Skip to content
Review Open access

Ferroptosis in metabolic dysfunction-associated steatotic liver disease

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 253 references
Medicine

TL;DR

Clinical, transcriptomic, and experimental data allow us to conceptualize hepatic ferroptosis as four interacting molecular modules: expansion of the labile pool of ferrous iron, enrichment of membranes with oxidizable polyunsaturated phospholipids, enzymatic and non-enzymatic lipid peroxidation, and failure of antioxidant defense.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread chronic liver disease that can progress from steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Its pathogenesis involves lipotoxicity, iron metabolism disorders, and oxidative stress—the same three processes that underlie ferroptosis, an iron-dependent form of regulated cell death mediated by the peroxidation of membrane phospholipids. However, the question of whether ferroptosis is a universal mechanism underlying the progression of MASLD as a whole or a hallmark of a distinct subgroup of patients remains unresolved. Furthermore, no ferroptosis-targeted strategy has yet been tested in a biomarker-selected population. This review addresses precisely this gap. Clinical, transcriptomic, and experimental data allow us to conceptualize hepatic ferroptosis as four interacting molecular modules: expansion of the labile pool of ferrous iron, enrichment of membranes with oxidizable polyunsaturated phospholipids, enzymatic and non-enzymatic lipid peroxidation, and failure of antioxidant defense. An imbalance in these modules leads to the accumulation of phospholipid hydroperoxides, disruption of membrane integrity, and immunogenic hepatocyte death with the release of signals that promote inflammation and fibrogenesis. At the same time, ferroptosis exhibits pronounced cellular and contextual specificity. It exerts a damaging effect on hepatocytes and sinusoidal endothelial cells, enhances inflammation in macrophages, but exerts an antifibrotic effect in activated stellate cells and immunosuppressive effects in lymphocytes. In this regard, known anti-ferroptotic strategies (iron chelation, inhibition of long-chain acyl-coenzyme A (CoA) synthase 4 (ACSL4)-dependent incorporation of polyunsaturated fatty acids, use of lipid radical scavengers and vitamin E, and activation of protective antioxidant programs) retain their diagnostic and therapeutic potential only within the framework of a molecularly and cell-stratified approach.

Read PDF

Similar papers

Review Open access Oct 2026

Targeting ferroptosis in metabolic dysfunction-associated steatotic liver disease: From mechanisms to cell type-specific therapeutic strategies (Review)

Metabolic dysfunction-associated steatotic liver disease (MASLD) impacts >30% of the global population. Its progression to metabolic dysfunction-associated steatohepatitis and liver fibrosis is the primary determinant for cirrhosis and hepatocellular carcinoma. Ferroptosis depends on iron and is driven by lipid peroxid...

Xiang Tao, Mei Liu · 0 citations
Review Open access Sep 2026

Ferroptosis in liver biology and diseases

This review aims to provide a comprehensive overview of the current molecular pathways and regulatory mechanisms underlying iron homeostasis and intracellular compartmentation in liver biology, emphasizing the roles of ferroptosis in several liver diseases.

Peng Cao, Pei-Jian He, Kuo Du et al. · 0 citations
Open access Nov 2026

Metabolic dysfunction-associated steatotic liver disease: the role of oxidative stress and emerging therapeutic strategies

Metabolic dysfunction-associated steatotic liver disease (MASLD) has attracted considerable global concern. Physical inactivity, excessive caloric intake and unhealthy lifestyle factors, have contributed to its development. Obesity and metabolic disorders are strongly correlated with MASLD. It is a complex condition ma...

R. Sharma, Abhilasha Tiwari, Parveen Kumar et al. · 0 citations
Review Open access Sep 2026

The convergent roles of metabolic dysfunction, alcohol, and iron in steatotic liver disease: a review

Abstract Steatotic liver disease (SLD) encompasses a broad spectrum of disorders influenced by metabolic dysfunction, alcohol use, and other cofactors. The updated classification of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), along with the recognition of...

Afolabi Akanbi, K. Bridle, D. Crawford · 0 citations
Review Open access Sep 2026

Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a leading cause of advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma. The disease develops through the interaction of multiple interconnected pathophysiological mechanisms, including in...

T. Radosavljević, J. Djuretić, M. Branković et al. · 0 citations
Review Open access Oct 2026

Ferroptosis in health and disease

Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death that is driven by lipid peroxidation. In the past decade, it has emerged as a core pathogenic mechanism in a wide range of human diseases, such as neurodegenerative disorders, cardiovascular disease, cancer, and notably, reproductive dysfuncti...

P. Oyedokun, V. Ashonibare, T. Akhigbe et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.